Safety data sheet
Standardized safety protocols and material specifications for professional use.
Certificate of Analysis
Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-gonadorelin-acetate-2mg
Gonadorelin Acetate (2mg)
Ultra High >99.5% Purity
Authorized Resellers
Available through our trusted partners
123peptide.com
Netherlands · Europe
local_shipping2-3 Business Days
Depeptidenwinkel.com
Netherlands · Europe
local_shipping2-3 Business Days
Scientific Background
Gonadorelin Acetate is a synthetic decapeptide identical in structure to endogenous Gonadotropin-Releasing Hormone (GnRH). Secreted in a pulsatile fashion from hypothalamic neurons, GnRH binds to receptors on anterior pituitary gonadotrophs to stimulate the synthesis and release of Luteinising Hormone (LH) and Follicle-Stimulating Hormone (FSH).
The pulsatile secretion pattern is critical — pulsatile GnRH stimulates gonadotropin release, whereas continuous exposure causes receptor downregulation and suppression. This pharmacological principle underlies both its use in hormone restoration research (pulsatile dosing) and as a diagnostic agent for testing hypothalamic-pituitary axis integrity.
In male reproductive research, gonadorelin is studied for its ability to maintain intratesticular testosterone levels, preserve spermatogenesis, and support axis recovery post-suppression. In female models it is explored for ovulation induction and cycle regulation. Its short half-life (~2–4 minutes IV, longer SC) makes it suitable for pulsatile administration protocols.
Intended Research Use
- Hypothalamic-pituitary-gonadal (HPG) axis restoration
- Testosterone and LH/FSH stimulation research
- Spermatogenesis preservation during gonadotropin suppression
- Post-cycle hormone axis recovery protocols
- Fertility hormone research (LH surge induction)
- Hypogonadotropic hypogonadism models
menu_bookScientific Publications
Endocrine Reviews (2004)
Gonadotropin-releasing hormone receptors: structure, function and overexpression in cancers
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/15082521/
Annual Review of Medicine (1994)
Gonadotropin-releasing hormone and its analogs
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/8198390/
American Journal of Men's Health (2019)
Pulsatile gonadorelin therapy achieves masculinisation without compromising reproductive organ development in isolated HH
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/30602396/
FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.
Possible stacks with other peptides
Synergistic combinations for enhanced research outcomes
Gonadorelin is typically combined with complementary endocrine peptides for comprehensive HPG axis restoration and reproductive research protocols.
HCG 5000IU (5000IU vial)
arrow_forwardmyo-hcg-5000iu
Comprehensive axis recovery — HCG provides direct Leydig cell stimulation for testosterone production while gonadorelin maintains the upstream pituitary signalling axis, creating dual-level HPG axis support.
HMG 75IU (75IU vial)
arrow_forwardmyo-hmg-75iu
FSH and LH coverage — HMG's balanced FSH/LH activity combined with gonadorelin's pituitary stimulation provides layered endocrine axis support in hypogonadotropic hypogonadism research.
Kisspeptin 10mg (10mg vial)
arrow_forwardmyo-kisspeptin-10-10mg
Upstream GnRH pathway activator — studied alongside Gonadorelin for complementary endocrine restoration and reproductive hormone regulation research.
Cycling Note: Protocols typically run 4–8 weeks with appropriate rest intervals. Gonadorelin dosing frequency must be maintained as pulsatile — avoid daily dosing.